Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Gastrointestinal and Hepatic Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1521715

The Median Effective Dose of Ciprofol Combined with a Low-dose Sufentanil for Gastroscopy in Obese or Nonobese Patients: A Dose-finding Study Using Dixon's Up-and-down Method

Provisionally accepted
Jie Zhao Jie Zhao 1YIxiao Zhang YIxiao Zhang 2Guowei Su Guowei Su 2Shaoyi Wang Shaoyi Wang 2Xiaolin Zhang Xiaolin Zhang 2Guoxiang Wang Guoxiang Wang 2Gang Chen Gang Chen 1*
  • 1 Department of Anesthesiology, Sir Run Run Shaw Hospital, School of Medicine, Graduate School, Zhejiang University, Hangzhou, China
  • 2 Hangzhou Red Cross Hospital, Hangzhou, Zhejiang Province, China

The final, formatted version of the article will be published soon.

    Objectives: Understanding the different pharmacodynamic responses to narcotics in patients with or without obesity is particularly important for the safety of gastroscopy sedation. This study aimed to determine the median effective dose (ED50) of ciprofol combined with lowdose sufentanil to inhibit the response to gastroscope insertion in obese or nonobese patients.Methods: A total of 27 obese patients (BMI 30-40 kg/m2) and 25 nonobese patients (BMI 18-25 kg/m2), aged between 18 and 65 years, with ASA physical status of 1-2, were included in this study. All patients underwent painless gastroscopy and received intravenous sufentanil at a dose of 0.1 μg/kg, followed by ciprofol administration. The initial dose of ciprofol for the first patient in both groups was 0.4 mg/kg, the subsequent dose was determined by the response of the previous patient to gastroscope insertion (cough, choking, body movement, etc.) using Dixon's up-and-down method. The dose was increased or decreased by 0.05 mg/kg depending on the observed responses. Data collection continued until 7 crossover points were obtained. Probit regression and bootstrapping methods were employed to calculate the median effective dose (ED50) and 95% confidence intervals (CIs). The ED50 values were then compared between the obese and nonobese patient groups.The ED50 of ciprofol combined with sufentanil inhibiting response to gastroscope insertion in patients with obesity was 0.186 mg/kg with 95% CI of 0.153~0.209 mg/kg, was significantly lower than patients with nonobese was 0.237 mg/kg with 95% CI of 0.206~0.253 mg/kg (p < 0.05).The ED50 values of ciprofol combined with sufentanil inhibiting response to gastroscope insertion in patients with obesity was lower than in patients with normal weight.

    Keywords: Ciprofol, Patients with obesity, Painless gastroscopy, Sufentanil, dosage exploration

    Received: 02 Nov 2024; Accepted: 29 Jan 2025.

    Copyright: © 2025 Zhao, Zhang, Su, Wang, Zhang, Wang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Gang Chen, Department of Anesthesiology, Sir Run Run Shaw Hospital, School of Medicine, Graduate School, Zhejiang University, Hangzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.